Anesiva Announces South Korea FDA Approval Of Adlea(TM) Investigational New Drug Application Anesiva, Inc. (Nasdaq: ANSV) announced that the South Korea Food and Drug Administration has approved Anesiva's investigational new drug application for Adlea(TM), the company's long-acting, site specific, non-opioid drug candidate in Phase 3 clinical development for the management of acute pain following orthopedic surgery. Anesiva plans to initiate a Phase 2 clinical trial of Adlea in patients undergoing arthroscopic shoulder surgery in South Korea this summer.
Source: www.medicalnewstoday.comResearcher Finds Link Between Pregnancy and Tooth Loss Title: Researcher Finds Link Between Pregnancy and Tooth Loss
Category:
Health News
Created: 6/4/2008 2:00:00 AM
Last Editorial Review: 6/4/2008
Source: www.medicinenet.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 5:00 PM
